European Wellness to Seal Further Pact with Hebei Sanzang Biotechnology, China, on Autism Project with Baoding Children’s Hospital to Facilitate Clinical Research and Biotechnology

MUNICH, Germany, May 11, 2025 – Germany and China have signed a bilateral framework agreement on cell therapy technology, reinforcing ties in biomedical innovation as part of a broader push to expand health and economic cooperation between the two nations.

The deal, between Germany’s European Wellness Biomedical Group and China’s Hebei Sanzang Biotechnology Co., Ltd., was formalised during the BWA–Baoding Cooperation Forum, held at the Pullman Hotel in Munich. The forum was hosted by the Federal Association for Economic Development and Foreign Trade (BWA) and gathered senior officials from both countries for high-level talks and signings.

Landmark Agreement on Stem Cell Innovation

The agreement, signed between Germany’s European Wellness Biomedical Group, represented by its Chairman Prof. Dr. Mike Chan, and China’s Hebei Sanzang Biotechnology Co., Ltd., represented by Chairman Liu Wei, outlines comprehensive collaboration in research and development, clinical trials, medical equipment exchange, and professional training.

The signatories—Prof. Dr. Mike Chan, Chairman of European Wellness, and Liu Wei, Chairman of Hebei Sanzang—stressed that the agreement aims to improve clinical application, exchange expertise, and elevate healthcare standards across both regions.

Under the agreement, both parties agreed to jointly explore clinical applications of stem cell therapy, conduct technical exchanges, and introduce internationally advanced therapeutic drugs and devices to improve treatment outcomes and research capabilities.

“Through this cooperation, we are not only transferring technology but building a future of precision medicine together,” said Prof. Mike Chan.

Four Key Agreements Signed in Munich

The cooperation on stem cell research was one of four agreements signed at the forum, reinforcing the growing strategic relationship between Germany and China.

The full list of agreements includes:

• Joint research and development in cell therapy:
  Both parties will collaborate on cutting-edge scientific studies to accelerate breakthroughs in regenerative treatment.
• Clinical trials in China to assess safety and effectiveness:
  Clinical testing will be conducted to validate the safety and efficacy of new cell-based therapies for wider application.
• Introduction of internationally advanced drugs and medical devices:
  European Wellness will help introduce high-quality, specialized therapeutic products and technologies to the Chinese market.
• Technical exchanges and professional training programs:
  Expert training sessions and personnel exchanges will be organized to strengthen clinical and research capabilities on both sides.

Forum Brings Together Senior German and Chinese Delegates

Held at the Pullman Hotel Munich, the BWA–Baoding Cooperation Forum attracted a strong turnout of senior officials, healthcare leaders, and business representatives from both countries.

Michael Schumann, president of BWA, led the German delegation, alongside Dr. Claus W. Biermann, Chairman of BWA’s Global Healthcare Committee, and Andreas Hube, Member of BWA Federal Management. Also present were Counsellor Guo Fang of the Chinese Consulate General in Munich, Thomas R. Meyer, Chairman of MR. PLAN GROUP, and Frank Behnam, Chairman of AQUANOVA AG.

The Chinese delegation was headed by Mayor Yan Jihong of the People’s Government of Baoding. She was joined by senior figures from government and industry, including Ma Yimin, Executive Deputy Director of Baoding High-Tech Industrial Zone, Jia Wenzhe, Mayor of Gaobeidian City, and Duan Xiuli, Director of Baoding’s Healthcare Security Bureau. Leaders from the private sector, such as Zhang Zhongqiang, President of Huitong Construction Group, and Liu Yu, Secretary-General of the Sino-German Alliance for Industry-Education Integration, also participated.

Why Baoding? A Strategic Hub for Medical Innovation

Baoding, located in northern China near Beijing and the Xiong’an New Area, has been chosen as the base for the first EHT (European Health Technology) Ecosystem due to its unique mix of strategic location, industrial development, and government support.

The Baoding International Medical Base spans approximately 2,200 hectares and is positioned to become a major medical innovation hub. The area is already home to over 100 leading medical enterprises and is projected to attract more, with total investments exceeding ¥100 billion (approx. USD 14 billion). The focus is on pharmaceutical R&D, precision medicine, high-end medical devices, and biotechnology.

Baoding’s innovation strategy also includes close collaboration with top-tier international research institutions and emphasizes AI-driven healthcare, smart hospital systems, and genomics. The region offers special policy zones that provide attractive tax incentives, land subsidies, and regulatory support aligned with China’s “Healthy China 2030” vision.

Beyond economic potential, the project is expected to have significant social impact by creating over 50,000 high-skilled jobs, improving healthcare access in the region, and reducing pressure on Beijing’s medical system through local availability of advanced treatments.

The slides presented during the BWA–Baoding Forum highlighted Baoding’s forward-thinking development plan, making it the ideal location for international cooperation in healthcare innovation.

A Broader Vision of Economic Diplomacy

This latest development follows the success of the Western Health Congress in Cologne (April 2024), which welcomed over 800 in-person participants and 500 online viewers under the theme “Ready for Change – Let’s Seize the Opportunity!” The congress laid the groundwork for greater international collaboration in healthcare innovation.

This new cooperation marks an exciting chapter for both countries. By combining resources and knowledge, Germany and China hope to speed up the development of treatments that could change lives. And with more projects planned in education and healthcare, this partnership is expected to grow even stronger in the years to come.

“This is how progress happens. It is more than just signing papers,” said Michael Schumann. “It’s about turning economic diplomacy into tangible progress in the field of science, education, and public health – through teamwork, shared vision, and action.”